Cellular energy has a supply chain.
Compounded injectable NAD+ with supplies, pharmacy fulfillment, and clinician guidance built around the route.
About 10 minutes. No charge unless your clinician approves.
Central to cellular energy. Not a shortcut to more of it.
NAD+, nicotinamide adenine dinucleotide, is not a supplement trend your body had never heard of. It is a coenzyme already present in cells throughout the body and involved in the chemistry that converts nutrients into usable cellular energy.
That central role is why NAD+ attracts so much attention in longevity conversations.
It also participates in enzyme systems involved in DNA repair, cellular stress responses, and metabolic regulation. Those mechanisms are real enough to be interesting without turning them into a promise that a compounded injection will make you feel younger, think faster, or recover like you did ten years ago.
This prescription uses subcutaneous delivery rather than an oral supplement route. Subcutaneous administration bypasses the oral route and places the compounded prescription into tissue rather than through digestion. That is a real formulation difference, but it does not by itself establish a particular clinical outcome. Your provider decides whether the formulation has a reasonable place in your broader plan.
You receive the supplies, storage instructions, administration guidance, and clinician follow-up needed to use the prescription as directed. Outcome expectations remain tied to research and your individual response.
Read the evidence →For the longevity reader who wants the biology before the promise.
The Fundamentals Are Already Handled
Sleep, training, nutrition, and ordinary medical care are not being neglected. You are interested in cellular-energy biology as a next conversation, not as a substitute for the basics.
The NAD+ Reader With Better Questions
You have seen dramatic claims about energy, focus, aging, and recovery. You want a clinician who can separate what NAD+ does inside cells from what a prescription has actually been shown to do for a person.
The Cellular-Energy Realist
You are less interested in chasing a feeling than in understanding whether an endogenous coenzyme with real metabolic importance belongs in a clinician-guided plan. You want the biology kept specific and the expectations kept honest.
Compounded NAD+ is not an FDA-approved drug product. Candidacy and dose are determined by a licensed provider from your full intake, and results vary.
This might not be the right fit if:
- You have an active cancer or are being treated for one. NAD+ can support the same cellular pathways that let cells multiply, so this needs oncology input first.
- You are pregnant or breastfeeding.
- You have significant kidney or liver disease. Talk with your provider before starting any injectable.
- You take a medication or carry a condition that deserves a closer look before adding an injectable compound.
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
NAD+, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Compounded NAD+ administered subcutaneously as directed by your provider
- Cellular-energy and NAD+-dependent enzyme biology kept separate from promised outcomes
- Medical history and current medications reviewed before prescribing
- Prepared to your individual prescription by a licensed 503A pharmacy
- Response and tolerability reviewed through ongoing care
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Longevity.
Semaglutide + B12 Microdose
A lower-dose path with B12 built in.
A lower-dose compounded semaglutide and B12 prescription for clinician-guided metabolic care at a different starting scale. (Contains semaglutide and vitamin B12.)
Tirzepatide + B12 Microdose
Dual-pathway biology at a lower starting scale.
A lower-dose compounded tirzepatide and B12 prescription that keeps dual-receptor biology inside clinician-led care. (Contains tirzepatide and vitamin B12.)
Metformin ER
Diabetes made it famous. Longevity made it interesting again.
FDA-approved generic metformin ER with decades of metabolic use and a serious place in the longevity conversation.
What the research shows
Intravenous NAD+ showed no measurable plasma rise for the first two hours.
The detail
In a human pilot study of eleven healthy men aged 30 to 55, the eight who received 750 mg of NAD+ by six-hour intravenous infusion showed no measurable rise in plasma NAD+ or its metabolites for the first two hours, with increased urinary excretion of NAD+ and methylnicotinamide detected at six hours.1
In heart failure, intravenous NAD+ improved ejection fraction; secondary endpoints did not reach significance.
The detail
In a single-center randomized, placebo-controlled trial of 180 adults with heart failure from ischemic cardiomyopathy, intravenous NAD+ at 10 mg daily for seven days improved left ventricular ejection fraction at one month compared with placebo, 45.44 percent versus 42.44 percent, while the secondary endpoints of NT-proBNP, major adverse cardiac and cerebrovascular events, and functional class showed trends that did not reach statistical significance.2
In human skin tissue, NAD+ levels correlated negatively with age.
The detail
In pelvic skin tissue from 49 human donors ranging from newborn to 77 years of age, NAD+ levels correlated negatively with age in both males and females, alongside age-associated increases in DNA damage and in PARP activity.3
Oral nicotinamide riboside, a precursor, raised blood NAD+ by about 60 percent.
The detail
In a two-period, six-week randomized, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults, 1000 mg per day of oral nicotinamide riboside, a precursor rather than NAD+ itself, was well tolerated and raised NAD+ in peripheral blood mononuclear cells by approximately 60 percent compared with placebo.4
Oral nicotinamide mononucleotide increased insulin-stimulated glucose disposal in women with prediabetes.
The detail
In a ten-week randomized, double-blind, placebo-controlled trial in postmenopausal women with prediabetes who were overweight or obese, oral nicotinamide mononucleotide, also a precursor rather than NAD+ itself, increased insulin-stimulated glucose disposal measured by hyperinsulinemic-euglycemic clamp and increased skeletal muscle insulin signaling, while placebo did not.5
Oral nicotinamide riboside and mononucleotide raised NAD metabolites; functional outcomes were often null.
The detail
In a PRISMA-guided systematic review of 113 intervention studies, including 33 human intervention studies, oral nicotinamide riboside and nicotinamide mononucleotide consistently raised NAD-related metabolites in humans and were generally well tolerated, while effects on functional, metabolic, and vascular outcomes were heterogeneous and often null.6
What it does not show
No randomized trial has tested injected NAD+ for energy, cognition, healthy aging or recovery.
The detail
No randomized controlled trial has evaluated injected or infused NAD+ for energy, cognition, healthy aging, or recovery, which is the reason most people consider this prescription. A systematic review of the literature through October 2025 identified no outcomes trial of intravenous or intramuscular NAD+ for anti-aging or wellness indications.
No published human study reports what subcutaneous NAD+ does to tissue levels or outcomes.
The detail
The human data on NAD+ itself come from routes and doses that are not what is offered here: a 750 mg six-hour intravenous infusion in a pilot study, and a seven-day course of intravenous NAD+ in patients hospitalized with heart failure from ischemic cardiomyopathy. No published human study reports what subcutaneous NAD+ does to tissue NAD+ levels or to any clinical outcome.
The most rigorous trials tested oral precursors, not NAD+ itself.
The detail
The most rigorous human trials in this category tested oral precursors, nicotinamide riboside and nicotinamide mononucleotide, rather than NAD+ itself. Those are different molecules given by a different route, and their results do not establish what an NAD+ injection does.
Correlation in skin samples does not establish that raising NAD+ by injection reverses anything.
The detail
The decline of NAD+ in aging human tissue is a correlation observed in skin samples. It does not establish that raising NAD+ by injection reverses an age-related outcome, and in the precursor trials biochemical target engagement did not reliably translate into improved functional outcomes.
- Grant R, et al. A pilot study investigating changes in the human plasma and urine NAD+… Front Aging Neurosci. 2019.
- Yu X, et al. Effect of nicotinamide adenine dinucleotide on heart failure caused by… Am J Cardiovasc Drugs. 2026.
- Massudi H, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human… PLoS One. 2012.
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and… Nat Commun. 2018.
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in… Science. 2021.
- Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided… Ageing Res Rev. 2026.
Serious risks
- Rate appears to be the variable that matters: the one controlled study using a slow six-hour infusion recorded no adverse events, while a clinic series in which patients set their own speed reported moderate to severe symptoms throughout
Commonly reported
- Nausea
- Abdominal cramping
- Chest pressure
- A faster heart rate
- These are commonly reported during the infusion and settle once it finishes
Because it is an injection
- This prescription is subcutaneous rather than intravenous
- With any injection there can be soreness, redness or swelling where you inject
Most of what is documented comes from intravenous NAD+. Your provider reviews cancer history, kidney and liver function, medications and pregnancy status before prescribing, because a coenzyme sitting inside cellular energy and repair pathways is not neutral in every body. Human safety data for compounded subcutaneous NAD+ is limited, which is the reason this sits with a clinician rather than in a shopping cart.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
There is not a defensible universal timeline for how a compounded NAD+ prescription will make an individual person feel. Your provider sets expectations from the reason treatment is being considered and evaluates response from what actually happens rather than promising energy, sleep, cognition, or recovery on a calendar.
This product is a compounded NAD+ prescription delivered by a subcutaneous route rather than an oral supplement. That route difference is factual. It does not by itself establish that the injection produces superior clinical outcomes, so your provider decides whether the formulation is worth considering for you.
Not everyone needs the same screening. Your clinician reviews your history and any recent results, then decides whether additional lab work is clinically useful before prescribing.
If NAD+ is prescribed, your care team provides the administration instructions specific to your prescription and remains available for technique or tolerability questions. You are not expected to determine injection technique or dosing on your own.
This compounded NAD+ prescription is not FDA-approved. No compounded medication is FDA-approved, including this one. NAD+ is a coenzyme found in every living cell and is central to cellular energy metabolism. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product. Your provider will talk this through as part of your evaluation.